Search the Newsreel

AtriCure (NASDAQ:ATRC) Sets New 12-Month High - Here's Why

AtriCure (NASDAQ:ATRC) reached a new 52-week high of $43.18, trading above its 50-day and 200-day moving averages. The company reported strong quarterly earnings, exceeding revenue estimates with $153.6 million and $0.18 EPS. Despite significant institutional ownership, insiders have sold shares totaling $1.78 million in …

ATRC: Strong growth, innovation, and clinical trial catalysts drive robust financial and market expansion

AtriCure, Inc. (ATRC) is experiencing strong growth and profitability, maintaining leadership in AFib and pain management. The company's financial performance is bolstered by innovation and operational leverage, with significant clinical trials expected to expand market opportunities. Free cash flow will be directed towards organic …

AtriCure (ATRC) Lifted Its Guidance, Is The Stock Fully Priced?

AtriCure (ATRC) has seen insider share sales despite reporting 13% Q2 revenue growth, returning to net income, and raising full-year guidance. While one valuation narrative suggests the stock is 11.9% undervalued at $47.00 due to potential market expansion from clinical trials, another analysis using …

Discipline and Rules-Based Execution in ATRC Response

This article analyzes Atricure Inc. (NASDAQ: ATRC), highlighting strong near and mid-term sentiment but a weak long-term outlook. It provides AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing support and …

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

Two AtriCure directors, including Maggie Yuen, sold shares after a strong second quarter where the company reported 13% revenue growth and raised its full-year outlook. Yuen sold 3,500 shares, reducing her direct equity stake by 20%, though the timing of sales by multiple directors …

AtriCure Inc (ATRC) Stock News Today

This article provides the latest stock news for AtriCure Inc (ATRC), detailing its current stock price, market capitalization, and performance metrics. It also highlights that more news, earnings, analyst ratings, and key developments will be available soon.

AtriCure (ATRC) director Maggie Yuen reports sale of 3,500 shares

AtriCure director Maggie Yuen sold 3,500 shares of Common Stock on August 5, 2026, at a weighted average price of $38.42 per share, totaling approximately $134,470. The shares were sold in multiple trades ranging from $38.37 to $38.43, and she now directly holds 14,015 …

AtriCure Inc (ATRC) Director Karen Prange Sells 3,564 Shares

AtriCure Inc (ATRC) Director Karen Prange sold 3,564 shares of the company on August 5, 2026, for a total value of approximately $138,283. This sale contributes to a pattern of 14 insider sells and no buys over the past year. The stock is currently …

Director At AtriCure Sells $134K Of Stock

AtriCure Director Maggie Yuen sold 3,500 shares of the company's stock for a total of $134,470, as reported in an SEC filing on August 7. The company's shares were trading up 2.89% at $39.49 following the report. AtriCure demonstrated strong revenue growth of 12.83% …

AtriCure director Maggie Yuen sells $134,470 in stock

AtriCure Director Maggie Yuen sold 3,500 shares of the company's common stock for $134,470 on August 5, 2026. This transaction leaves Yuen with 14,015 shares. The sale occurred while AtriCure's stock is trading near its 52-week high, despite the company recently surpassing Q2 2026 …

AtriCure, Inc. (ATRC) director sells 3,564 shares at $38.80

AtriCure, Inc. director Karen Prange sold 3,564 shares of common stock at $38.80 per share on August 5, 2026, in an open market or private transaction. Following this sale, Prange directly holds 22,809 shares of AtriCure. The transaction was reported in a Form 4 …

AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of "Moderate Buy" from Analysts

AtriCure, Inc. (NASDAQ:ATRC) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $48.50. The company recently reported strong quarterly results, exceeding EPS and revenue estimates, and provided positive fiscal year 2026 guidance. While institutional ownership is high …

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Key Points Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the company. All transacted shares were held directly; the director …

AtriCure, Inc. SEC Filing (Aug 5, 2026)

This article reports on an SEC Form 144 filing by AtriCure, Inc. (ATRC) on August 5, 2026. The filing indicates a proposed sale of 3,500 common shares acquired through restricted stock, with an aggregate market value of $134,467.90, to be sold via Morgan Stanley …

AtriCure (ATRC) insider plans NASDAQ sale of 3,564 awarded shares

AtriCure, Inc. insider Karen Prange has filed a notice of intent to sell 3,564 shares of common stock on NASDAQ, which were awarded on May 26, 2023. This Form 144 filing indicates that the shares are held through Fidelity Brokerage Services LLC. Over the …

Project Horizon and Outlook Upgrade Might Change The Case For Investing In Inspire Medical Systems (INSP)

Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly revenue of US$200.58 million and earnings of US$0.14 per share that exceeded analyst expectations despite …

Will AtriCure’s (ATRC) Profit Turn and ESOP Share Plans Recast Its Investment Narrative?

AtriCure (ATRC) recently reported a shift to net income in Q2 2026, with higher revenue and positive full-year guidance, suggesting improving operating leverage. While ESOP-related share registrations indicate potential dilution, the company's profitability and guidance update strengthen its investment narrative, though competitive pressures from …

Form 4 AtriCure Inc For: 3 August By Investing.com

This article reports on a Form 4 filing for AtriCure Inc. (ATRC) on August 3rd. It is a brief, factual announcement from Investing.com, providing no additional details or analysis beyond the filing date and company. The article also includes various market data and related …

AtriCure, Inc. (ATRC) CEO makes 4,700-share stock gifts to family, charity

Michael H. Carrel, CEO of AtriCure, Inc. (ATRC), reported bona fide gifts of 4,700 shares of common stock on July 30, 2026. These gifts included 700 shares to a parent and 4,000 shares to a charity, all without consideration. The filing also details his …

Board Member At AtriCure Exercises Options Worth $491K

Sven Wehrwein, a Board Member at AtriCure (NASDAQ: ATRC), exercised stock options worth $491,500 for 25,000 shares on July 30, according to an SEC filing. Despite the insider transaction, AtriCure shares were down by 6.06% on Friday morning. The article also provides a financial …

AtriCure (ATRC) Looks Repriced As Strong Q2 Earnings And Higher Guidance Reset The Story

AtriCure (ATRC) has seen significant repricing following strong Q2 earnings, reporting US$153.6 million in revenue and US$8.96 million in net income, coupled with raised 2026 guidance. While recent stock performance has been robust, opinions diverge on its valuation, with some models suggesting it is …

AtriCure, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ATRC) 2026-07-30

AtriCure, Inc. (ATRC) published its Q2 2026 earnings call presentation on July 30, 2026. The company reported EPS of $0.18, beating estimates by $0.16, and revenue of $153.60 million, a 12.83% year-over-year increase, beating estimates by $1.79 million. This article provides access to the …

AtriCure (NASDAQ: ATRC) director exercises 25,000 options and sells 25,000 shares

AtriCure director Sven Wehrwein exercised 25,000 non-qualified stock options at $19.95 per share and subsequently sold all 25,000 resulting shares at a weighted average price of $37.84 per share on July 28, 2026. Following these transactions, no options remain outstanding under this specific grant, …

AtriCure, Inc. (ATRC) insider sells 6,182 shares at $38.80

AtriCure, Inc.'s Chief Marketing & Strategy Officer, Justin J. Noznesky, sold 6,182 shares of common stock on July 29, 2026, at a weighted average price of $38.80 per share. The transaction, executed in multiple trades, resulted in Noznesky directly holding 100,219 shares of the …

Are Options Traders Betting on a Big Move in AtriCure Stock?

Options traders are showing significant interest in AtriCure (ATRC) stock, with the Sep 18, 2026 $50 Call exhibiting high implied volatility, suggesting expectations of a large price movement. Despite this, analysts currently rate AtriCure as a Zacks Rank #3 (Hold), and recent earnings estimates …

Is AtriCure (ATRC) A Bargain Following Its New Share Registration Filings?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. AtriCure (ATRC) drew fresh investor attention after filing two shelf registrations related to employee stock ownership offerings, covering up to 2,250,000 common shares and approximately …

ETFs Investing in AtriCure, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold shares of AtriCure, Inc. (ATRC). It provides a comprehensive table detailing each fund's market value, weight of ATRC stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and …

UC co-op helps build career pathways at AtriCure

The article highlights the strong partnership between the University of Cincinnati's co-op program and AtriCure, a medical device company. Many UC students, especially in biomedical engineering, gain invaluable real-world experience at AtriCure, with numerous alumni continuing to work there full-time. This collaboration provides significant …

AtriCure (ATRC) investor plans to sell 6,000 shares in Rule 144 filing

A shareholder of AtriCure, Inc. (ATRC), Vinayak Doraiswamy, has filed a Form 144 to sell 6,000 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services. The proposed sale is scheduled for July 28, 2026, with an aggregate market value of $233,278.80. These …

AtriCure, Inc. SEC Filing (Jul 28, 2026)

This article details an SEC Form 144 filing by AtriCure, Inc. (ATRC) on July 28, 2026, indicating a proposed sale of 25,000 shares of common stock with an aggregate market value of $964,444.00. The shares were acquired through a stock option exercise from the …

AtriCure, Inc. (ATRC) Beat Earnings Estimates. Here’s What Could Drive ATRC Stock Next

AtriCure, Inc. 2026: Revenue $153.6M, EPS $0.18— 10-Q Summary

AtriCure, Inc. reported its 2026 quarter results, showing a significant revenue increase to $153.6M, up 12.8% year-over-year. The company returned to net income with diluted EPS of $0.18, compared to a loss in the prior year. Growth was driven by strong U.S. demand and …

AtriCure, Inc. Quarterly Earnings Report

AtriCure, Inc. (ATRC) filed its Form 10-Q for the quarter ended June 30, 2026, reporting $167,786 thousand in cash and $61,000 thousand in debt. The company achieved $9,063 thousand in net income and $18,196 thousand in operating cash flow for the six months, a …